BRAF and neoplasm: While a higher tumour burden and lower TILs has previously been shown to be associated with poor response to immunotherapy [10,33,34], our study is the first to demonstrate that these factors, in addition to a BRAF mutation, also discriminate rapid progressors from other progressors in melanoma.